These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22076430)

  • 1. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
    Zhang B; Xie S; Shi W; Yang Y
    Nephrol Dial Transplant; 2012 May; 27(5):1746-55. PubMed ID: 22076430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.
    Ma J; Zhang B; Liu S; Xie S; Yang Y; Ma J; Deng Y; Wang W; Xu L; Li R; Zhang L; Yu C; Shi W
    PLoS One; 2013; 8(5):e64912. PubMed ID: 23741418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes.
    Xu LB; Chi N; Shi W
    Genet Mol Res; 2015 Aug; 14(3):9518-29. PubMed ID: 26345885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Amiloride reduces proteinuria and inhibits podocyte uPAR in the 5/6 nephrectomy rats].
    He C; Zhang B; Xie S; Yang Y; Ma J; Shi W
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Nov; 34(11):1654-7. PubMed ID: 25413068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
    Zhang B; Shi W; Ma J; Sloan A; Faul C; Wei C; Reiser J; Yang Y; Liu S; Wang W
    J Mol Med (Berl); 2012 Dec; 90(12):1407-20. PubMed ID: 23015147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [11R-VIVIT inhibits the expression of urokinase-type plasminogen activator receptor in podocytes].
    Li R; Shi W; Ma J; Zhang B; Zhang L; Liang X; Chen Y; Liu S; Wang W
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul; 33(7):1022-6. PubMed ID: 23895845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor.
    Wu MJ; Chang CH; Shu KH; Ho HC; Li JR; Fu YC
    Transplant Proc; 2014 May; 46(4):1226-8. PubMed ID: 24815166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes.
    Lang Y; Zhao Y; Zheng C; Lu Y; Wu J; Zhu X; Zhang M; Yang F; Xu X; Shi S; Liu Z
    Cell Death Dis; 2019 May; 10(6):401. PubMed ID: 31127093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
    Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC
    J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
    Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.
    Raij L; Tian R; Wong JS; He JC; Campbell KN
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1308-F1317. PubMed ID: 27335373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of kidney barrier function by the urokinase receptor.
    Wei C; Möller CC; Altintas MM; Li J; Schwarz K; Zacchigna S; Xie L; Henger A; Schmid H; Rastaldi MP; Cowan P; Kretzler M; Parrilla R; Bendayan M; Gupta V; Nikolic B; Kalluri R; Carmeliet P; Mundel P; Reiser J
    Nat Med; 2008 Jan; 14(1):55-63. PubMed ID: 18084301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Src is in the effector pathway linking uPAR and podocyte injury.
    Kopp JB; Heymann J
    J Clin Invest; 2019 Apr; 129(5):1827-1829. PubMed ID: 30939121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy.
    Sakurai N; Kuroiwa T; Ikeuchi H; Hiramatsu N; Takeuchi S; Tomioka M; Shigehara T; Maeshima A; Kaneko Y; Hiromura K; Kopp JB; Nojima Y
    Nephrol Dial Transplant; 2009 Aug; 24(8):2378-83. PubMed ID: 19188342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
    Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
    Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome.
    Koshikawa M; Mukoyama M; Mori K; Suganami T; Sawai K; Yoshioka T; Nagae T; Yokoi H; Kawachi H; Shimizu F; Sugawara A; Nakao K
    J Am Soc Nephrol; 2005 Sep; 16(9):2690-701. PubMed ID: 15987752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
    Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
    Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model.
    Cheng CC; Lee YF; Lan JL; Wu MJ; Hsieh TY; Lin NN; Wang JM; Chiu YT
    Lupus; 2013 May; 22(6):554-61. PubMed ID: 23478030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.